NanoString Enhances Solid Tumor Profiling with 3D Biology Capabilities for Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples
nCounter® Vantage 3D™ Solid Tumor Panels Enable Simultaneous Analysis of Single Nucleotide Variations (SNVs), mRNA, Fusion Genes, and Proteins on a Single Platform
SEATTLE — NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of two new translational research assays in the company’s Vantage 3D product line at the American Society of Human Genetics (ASHG) Annual Meeting in Vancouver Canada:
nCounter Vantage 3D DNA (SNV) Solid Tumor Panel
nCounter Vantage 3D Protein Solid Tumor Signaling Pathways Panel
The two new panels can be combined with one another as well as with the nCounter Vantage RNA Panels to enable more comprehensive profiling of formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The nCounter Vantage 3D Solid Tumor portfolio provides a deeper understanding of genotype and phenotype in various solid tumor cancers by enabling multiplexed, di

